85873-34-3

Upstream product

• 24126-61-2 methyl 4-(2-cyanoethoxy)benzoate 
• 99-76-3 methyl 4-hydroxylbenzoate 
• 85873-33-2 p-(3-<(1-Benzyloxy)formamido>-propoxy)benzoesaeuremethylester 
• 773875-80-2 methyl 4-[3-(1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl)propoxy]benzoate 

Downstream Products

• 153938-39-7 methyl 4-(3-benzenesulfonylaminopropoxy)benzoate 
• 1401355-80-3 4-(3-aminopropoxy)benzoic acid hydrochloride 
• 1198395-26-4 methyl 4-(3-(2-amino-5-nitroso-6-oxo-1,6-dihydropyrimidin-4-ylamino)propoxy)benzoate 

Relevant academic research and scientific papers

Dual inhibitor for prolyl hydroxylase and histone deacetylase, preparation method and application thereof

The invention discloses a new dual inhibitor for prolyl hydroxylase and histone deacetylase shown as formula I, a preparation method and an application thereof. The new dual inhibitor is capable of selectively promoting the level of hypoxia-inducible fact

SELECTIVE GLUCOCORTICOID RECEPTOR LIGANDS

Described herein are certain steroid derivative compounds, for example of formula (I): wherein X1, X2, X3 L, and Ar are as defined herein, pharmaceutical compositions comprising such compounds, the use of such compounds and compositions to specifically target glucocorticoid action, and the use of such compounds and compositions in the treatment of acute and chronic inflammatory conditions, in particular rheumatoid arthritis, haematological and other malignancies, and for causing immunosuppression in the prevention or treatment of transplant rejection, as well as methods of preparing such compounds.

PROCESS FOR PREPARATION OF DRONEDARONE BY N-BUTYLATION

The invention relates to a novel process for preparation of dronedarone (I) and pharmaceutically acceptable salts thereof where the compound of formula (II) or salt thereof is reacted with a compound of formula L-(CH2)3—CH3 (III), where L is a leaving group, and isolating the obtained product and, if desired, converting it into a pharmaceutically acceptable salt thereof. The invention also relates to some novel intermediary compounds and the preparation thereof.

REDUCTIVE AMINATION PROCESS FOR PREPARATION OF DRONEDARONE USING AMINE INTERMEDIARY COMPOUND

The invention relates to a novel process for preparation of drohedarone of formula (I) and pharmaceutically acceptable salts thereof characterized in that a compound of formula (II) is reacted in the presence of a reductive agent with butyraldehyde and/or butanoic acid, and isolating the obtained product and, if desired, converting it into a pharmaceutically acceptable salt thereof. The invention also relates to some hovel intermediary compounds and the preparation thereof.

PROCESS FOR PREPARATION OF DRONEDARONE BY N-BUTYLATION

The invention relates to a novel process for preparation of dronedarone (I) and pharmaceutically acceptable salts thereof where the compound of formula (II) or salt thereof is reacted with a compound of formula L-(CH2)3-CH3 (III), where L is a leaving group, and isolating the obtained product and, if desired, converting it into a pharmaceutically acceptable salt thereof. The invention also relates to some novel intermediary compounds and the preparation thereof.

REDUCTIVE AMINATION PROCESS FOR PREPARATION OF DRONEDARONE USING AMINE INTERMEDIARY COMPOUND

The invention relates to a novel process for preparation of drohedarone of formula (I) and pharmaceutically acceptable salts thereof characterized in that a compound of formula (II) is reacted in the presence of a reductive agent with butyraldehyde and/or butanoic acid, and isolating the obtained product and, if desired, converting it into a pharmaceutically acceptable salt thereof. The invention also relates to some hovel intermediary compounds and the preparation thereof.

Structural studies of pterin-based inhibitors of dihydropteroate synthase

Dihydropteroate synthase (DHPS) is a key enzyme in bacterial folate synthesis and the target of the sulfonamide class of antibacterials. Resistance and toxicities associated with sulfonamides have led to a decrease in their clinical use. Compounds that bi

Synthesis and activities of new arylsulfonamido thromboxane A2 receptor antagonists

New benzoic, benzeneacetic and thiazole-4-acetic acids bearing an arylsulfonamido alkyl or alkylhetero side chain were synthesized and tested in vitro for affinity for human platelet thromboxane A2 receptors and inhibition of U46619-induced rat aortic ring contraction.Influence of substitution patterns, chain length and presence of heteroatoms were studied and compounds within a 30 nmol range for inhibition of U46619-induced contractions were found.One of the most potent, 2-thiazole-4-acetic acid (VII-4) was orally active (1 mg/kg), as evidenced by the inhibition of U46619-induced platelet aggregation in guinea pigs, ex vivo. thromboxane A2 / receptor antagonist / platelet aggregation / arylsulfonamido derivative

42. Reinigung der D-Oxynitrilase aus Mandeln mit Hilfe der Affinitaets-Chromatographie

Oxynitrilase from almond meal is capable of catalysing the stereospecific addition of cyanide to a variety of aldehydes.Thus, the enzyme is potentially useful in the synthesis of optically active cyanohydrins on a preparative scale .As the currently av